Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

Leukemia Research Reports

Volumn 4, Issue 2, 2015, Pages 60-63

  Blunt, Matthew D ^a   Steele, Andrew J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

CLL; Duvelisib; Idelalisib; PI3K

Indexed keywords

2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ANTINEOPLASTIC AGENT; BUPARLISIB; COPANLISIB; DUVELISIB; EVEROLIMUS; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PILARALISIB; RITUXIMAB; TGR 1202; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; CONCENTRATION RESPONSE; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LEUKEMIA CELL LINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW;

EID: 84942244150     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2015.09.001     Document Type: Review

References (23)

1. Stevenson F.K., et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118(16):4313-4320.
2. Jain P., et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015, 125(13):2062-2067.
3. Dong S., et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 2014, 124(24):3583-3586.
4. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 2013, 31:675-704.
5. Niedermeier M., et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009, 113(22):5549-5557.
6. Herman S.E., et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116(12):2078-2088.
7. Kienle D., et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006, 107(5):2090-2093.
8. Brown J.R., et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014, 123(22):3390-3397.
9. Furman R.R., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014, 370(11):997-1007.
10. Ali K., et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014, 510(7505):407-411.
11. de Rooij M.F., et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood 2015, 125(14):2306-2309.
12. Winkler D.G., et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 2013, 20(11):1364-1374.
13. Balakrishnan K., et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145, overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 2015, 29(9):1811-1822.
14. IPI-145 shows promise in CLL patients. Cancer Discov., 4(2), 2014, 136.
15. Peng J., et al. Phosphoinositide 3-kinase p110delta promotes lumen formation through the enhancement of apico-basal polarity and basal membrane organization. Nat. Commun. 2015, 6:5937.
16. Brown J.R., et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin. Cancer Res. 2012, 18(14):3791-3802.
17. Iyengar S., et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013, 121(12):2274-2284.
18. de Frias M., et al. Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells. Br. J. Haematol. 2010, 150(1):108-111.
19. Gockeritz E., et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int. J. Cancer 2015.
20. Amrein L., et al. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int. J. Cancer 2013, 133(1):247-252.
21. Brown J.R., et al. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma. Clin. Cancer Res. 2015, 21(14):3160-3169.
22. Shull A.Y., et al. RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget 2015, 6(16):14632-14645.
23. Blunt M.D., et al. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Emu-TCL1 mouse model. Blood 2015, 125(26):4032-4041.